Key Takeaways
- Atomic Alchemy, Oklo’s subsidiary, obtained its inaugural NRC materials license for isotope handling, processing, and distribution at its Idaho facility.
- This regulatory approval creates the company’s first opportunity for commercial revenue through isotope sales from the Idaho Radiochemistry Laboratory.
- The approval applies only to isotope operations — Oklo’s primary advanced reactor technology still requires separate NRC authorization before power generation can begin.
- A separate agreement with the U.S. Department of Energy was announced to facilitate Oklo’s initial reactor project at Idaho National Laboratory.
- Shares climbed 4.6% during premarket hours before the company’s quarterly earnings report scheduled for Tuesday evening.
Oklo reached a significant regulatory checkpoint on Tuesday, although with important limitations. The Nuclear Regulatory Commission granted its first materials license — issued to Atomic Alchemy, the wholly-owned subsidiary Oklo acquired in 2025, rather than to the parent company directly.
This authorization permits Atomic Alchemy to accept, store, manipulate, and sell isotopes from its Idaho Falls-based Idaho Radiochemistry Laboratory. The license specifically covers handling up to 2 Curies of Ra-226, plus Co-60 and Am-241 for calibration applications.
These isotopes serve critical roles in medical treatments, scientific research, industrial manufacturing, and national defense applications. Oklo’s CEO Jacob DeWitte highlighted the market gap: “Demand for critical isotopes is rising, but U.S. supply remains limited.”
This development creates genuine near-term commercial possibilities. Atomic Alchemy can now launch revenue-generating isotope sales from its Idaho operations, representing the first income-producing activity across Oklo’s entire enterprise. The parent company has yet to record any revenue.
Crucially, this license differs from the reactor authorization investors have been anticipating. Oklo’s advanced fast reactor technology continues moving through NRC evaluation channels. Until that separate approval arrives, the company cannot commercialize electricity generation — which represents its primary long-term business model.
Scope of the Regulatory Approval
The NRC issued the license following comprehensive evaluation procedures and physical inspection of the Idaho location. Atomic Alchemy intends to reclaim and repurpose retired radium sources — materials previously classified as waste — converting them into valuable feedstock for medical isotope manufacturing, particularly for targeted alpha therapy applications.
Beyond immediate operations, the laboratory supports broader strategic objectives. Atomic Alchemy is advancing plans for a multi-reactor isotope production complex featuring up to four Versatile Isotope Production Reactor (VIPR) units, each designed for approximately 15 MWth output capacity.
Tuesday’s announcements included additional news. Oklo revealed a new cooperative agreement with the U.S. Department of Energy to facilitate planning, construction, and operation of its inaugural reactor at Idaho National Laboratory through the DOE’s Reactor Pilot Program.
Tech Giant Partnership and Earnings Anticipation
Oklo’s nuclear energy vision has secured backing from a major technology company. The firm maintains a partnership with Meta Platforms for developing a nuclear energy campus in Ohio’s southeastern region. BofA Securities characterized this arrangement as “one of a few firm, binding partnerships today” across the emerging nuclear sector.
Shares advanced 4.6% in premarket activity on Tuesday following the announcements. Oklo’s quarterly financial results are slated for release after trading concludes that same evening.
The company projects achieving commercial nuclear power generation between late 2027 and 2028.
